(KPC) [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . CAZ-AVI represents a potentially powerful tool for managing these infections in light of its demonstrated in vitro activity against CRE isolates that produce KPC enzymes (as well as extended-spectrum β-lactamases, AmpC β-lactamases, and oxacillinases) [16] . However, there is a paucity of clinical evidence on the efficacy of CAZ-AVI in humans with CRE infections. In the phase 2 and 3 clinical trials conducted to support its marketing authorization in Europe and the United States [17] [18] [19] [20] [21] , CAZ-AVI was tested against carbapenems, which, prior to 2015, were considered the "best available therapy" for infections caused by ceftazidime-resistant Enterobacteriaceae. As a result, individuals whose infections were caused by carbapenem-resistant isolates were excluded from enrollment in these trials. CAZ-AVI's performance in this setting has, however, been assessed in retrospective studies of patients whose CRE infections were treated with the drug, although in these studies a relatively limited number of patients was considered [22] [23] [24] [25] . Size-related limitations are in particular a feature of the 2 cohort studies in which the efficacy and safety of CAZ-AVI therapy for CRE infections was compared with that of alternative antimicrobial regimens [26, 27] .
To address this knowledge gap, we conducted a retrospective multicenter study of 138 Italian patients with documented KPC-producing K. pneumoniae (KPC-Kp) infections, all of whom received CAZ-AVI as salvage therapy. Our aims were to document the clinical features and outcomes of these cases and to specifically explore outcomes and predictors of mortality in patients with KPC-Kp bacteremia.
METHODS

Study Design
We conducted a retrospective observational study of inpatients in 17 Italian hospitals who were treated for KPC-Kp infections between 1 April 2016 and 31 December 2017. The study protocol was approved by the Research Ethics Committee of the coordinating center (Fondazione Policlinico Universitario -Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) "Agostino Gemelli, " Catholic University of the Sacred Heart, Rome), and the informed consent requirement was waived because of the study's retrospective, noninterventional nature.
CAZ-AVI was not available for routine clinical use in Italy during the study period. The patients making up the cohort had therefore received CAZ-AVI salvage therapy within the bounds of compassionate-use programs administered by the drug's manufacturers (AstraZeneca and, later, Pfizer). Neither company had any other type of involvement in the study.
Cases were eligible for inclusion in the cohort if the patient (1) was ≥18 years old; (2) had had a culture-confirmed KPC-Kp infection; and (3) had received ≥72 hours of CAZ-AVI salvage therapy (with or without other antimicrobials). CAZ-AVI was administered intravenously at a dose of at 2.5 g every 8 hours, with dosage adjustments for renal impairment, as recommended by the manufacturers.
Descriptive statistics were computed to summarize the characteristics (demographic, clinical, and epidemiological) of the infections, their treatment, and their outcomes (ie, 30-day mortality). Infections were classified as KPC-Kp bacteremia if (1) blood cultures were positive for a KPC-Kp strain (with or without KPC-Kppositive cultures from 1 or more other sites), and (2) there were clinical signs of the systemic inflammatory response syndrome. Nonbacteremic KPC-Kp infections were defined by (1) documented recovery of a KPC-Kp isolate from cultures of nonblood samples (eg, intra-abdominal wounds, urine, sputum, bronchoalveolar lavage fluid); (2) no blood culture positivity for KPC-Kp during the index hospitalization; and (3) clinical signs of infection. Treatment regimens containing CAZ-AVI were classified as combination therapy if they included at least 1 other antimicrobial (administered for ≥72 hours) displaying activity against the KPC-KP isolate. Relapse was defined as the onset, during the index hospitalization, of a second microbiologically documented KPC-Kp infection in a patient whose original infection had been classified as a clinical cure (with or without microbiological confirmation).
Our secondary aim was to assess the efficacy of CAZ-AVI specifically in patients with KPC-Kp bacteremia. To this end, we analyzed case characteristics and outcomes in the subcohort of patients whose CAZ-AVI-treated KPC-Kp infections were bacteremic (cases), as defined above. Findings were compared with those on a matched cohort of patients whose bacteremic KPC-Kp infections had been managed in the participating centers receiving ≥72 hours of salvage therapy regimens that did not include CAZ-AVI (controls). Case-control matching was based on (1) the number of days (± 1 day) from bacteremia onset to the initiation of salvage therapy and (2) Pitt bacteremia scores (± 1 point) [28] . We also analyzed data on survivor and nonsurvivor subgroups in the combined group of bacteremia patients (cases plus controls) to identify predictors of 30-day mortality.
Definitions
The following terms were defined prior to data analysis:
• Hospital admission was the date the patient was admitted to the study facility.
• Infection onset was the collection date of the index culture (ie, the first culture that yielded the study isolate).
• Septic shock was sepsis associated with organ dysfunction and persistent hypotension despite volume replacement [29] .
• Clinical failure was persistence of signs and symptoms from baseline to the end of antibiotic therapy.
• Microbiological failure was persistence of positive cultures (evaluated only in patients with repeated cultures available).
• Salvage therapy was antibiotic therapy administered after clinical and/or microbiological failure of a first-line treatment regimen or when it had not been possible to continue the previous therapy because of the onset of severe side effects (eg, acute renal failure or allergic reactions).
• High-risk bacteremic infections were those with unidentified sources or identified sources other than urinary tract or biliary tract infections.
Microbiology
Isolates were identified with the Vitek 2 system (bioMérieux, Marcy l'Etoile, France) or matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI Biotyper, Bruker Daltonics GmbH, Leipzig, Germany, or Vitek-MS, bioMérieux). Each hospital conducted antibiotic susceptibility testing according to its own protocols, in most cases using the Vitek 2 system (bioMérieux) or the Sensititre broth microdilution method (Trek Diagnostic Systems, Cleveland, Ohio).
CAZ-AVI susceptibility was tested by disk diffusion or broth microdilution. Results were interpreted in accordance with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints. Phenotypic detection of carbapenemase types was performed according to EUCAST guidelines [30] . Genotypic detection of carbapenemases was performed for a subset of isolates by using the eazyplex SuperBug CRE assay (Amplex Diagnostics GmbH, Germany) or the Xpert Carba-R assay (Cepheid, Italy).
Statistical Analysis
Results are expressed as mean ± standard deviation or median and interquartile range (IQR) (continuous variables) or as percentages of the group from which they were derived (categorical variables). The Student t test and Mann-Whitney U test were used to compare normally and nonnormally distributed continuous variables, respectively. Categorical variables were evaluated with the χ 2 or the Fisher exact test. Odds ratios and 95% confidence intervals were calculated for all associations that emerged. Two-tailed tests were used to determine statistical significance; a P value of <.05 was considered significant. Multivariate logistic regression analysis was used to identify independent risk factors for 30-day mortality. Variables emerging from univariate analysis with P values of <.1 were included in the multivariate model in a backward stepwise manner. A propensity score for receiving therapy with CAZ-AVI was added to the model. The propensity score was calculated using a nonparsimonious multivariate logistic regression model in which the outcome variable was the treatment with CAZ-AVI. The Kaplan-Meier method was used for survival analysis. All statistical analyses were performed with the Intercooled Stata program, version 11.
RESULTS
Characteristics and Outcomes of the Study Cohort
Clinical and Microbiological Characteristics
As shown in Figure 1 , during the study period, 154 patients in the participating centers received CAZ-AVI salvage therapy for an infection caused by carbapenem-resistant gram-negative bacteria, and in 97% of the cases (n = 149), the organism was a KPC-Kp. Eleven of the 149 KPC-Kp infections were excluded from the study because the case failed to meet 1 or more inclusion criteria. All 138 KPC-Kp isolates were resistant to penicillins, extended-spectrum cephalosporins, ertapenem, and ciprofloxacin, and most (129/138 [93.5%]) had meropenem minimum inhibitory concentrations (MICs) of ≥16 mg/L. At the outset of salvage therapy, all isolates displayed in vitro susceptibility to CAZ-AVI; some were also susceptible to gentamicin (41%), fosfomycin (39%), tigecycline (32%), colistin (27%), or amikacin (16%).
Salvage Treatment Regimens and Outcomes
As shown in Table 1 (Figure 1) . Three of the patients who died (2.2% of the entire cohort) (2 with bacteremia, 1 with pneumonia) had persistently positive cultures after starting CAZ-AVI treatment, and their isolates eventually developed in vitro resistance to the drug. Two of the 3 were treated with CAZ-AVI monotherapy, and 1 of the 2 received chronic renal replacement therapy. During the index hospitalization, 12 of the 138 (8.7%) patients (10 with bacteremia, 1 with a urinary tract infection, 1 with pneumonia) experienced KPC-Kp infection relapses after CAZ-AVI treatment was discontinued (median interval, 23 days). In all 12 cases, the KPC-Kp isolates remained susceptible to CAZ-AVI, and clinical and/or microbiological cures were achieved after retreatment with CAZ-AVI plus gentamicin. Table 2 shows the demographic and clinical characteristics of the 104 patients with KPC-Kp bacteremia treated with CAZ-AVI salvage therapy (cases) and those of the matched cohort whose KPC-Kp bloodstream infections (BSIs) were managed with second-line regimens containing drugs other than CAZ-AVI (controls). Thirty-day survival rates of CAZ-AVI treated bacteremic patients according to concomitant drugs used as combination therapy or to CAZ-AVI monotherapy is reported in Figure 2 , whereas antibiotic salvage regimens that received control patients are shown in Supplementary  Table 1 .
Outcomes and Predictors of Mortality in Patients With KPC-Kp Bacteremia Treated With CAZ-AVI Versus Other Regimens
The 30-day mortality rate among KPC-Kp bacteremia patients who received CAZ-AVI was significantly lower than that of controls (36.5% vs 55.8%, P = .005) ( Table 2) . Among patients managed with single-drug salvage treatment regimens, those who received CAZ-AVI displayed significantly lower 30-day mortality than those treated with alternative single-drug regimens ( Tables 3 and 4 , respectively. In the multivariate analysis, septic shock at the start of salvage therapy, neutropenia, Charlson comorbidity index ≥3, and recent mechanical ventilation emerged as independent predictors of mortality, whereas treatment with CAZ-AVI (with or without other active drugs) was the only variable independently associated with survival. After adjustment for the propensity score in the logistic regression model evaluating risk factors for mortality, all the variables remained in the model without significant differences (Table 4) . Survival curve analysis confirmed the reduced mortality risk associated with CAZ-AVI treatment (P < .001), even after adjustment for septic shock at the start of salvage therapy (Figure 3 ).
DISCUSSION
The past decade has witnessed a global increase in the prevalence of CRE infections, particularly those caused by K. pneumoniae. CRE infections (especially those characterized by bacteremia) are associated with high morbidity and mortality [3] , and the options for their treatment are very limited. Clinical trial data on the management of these infections are lacking. However, findings from observational studies have supported the use of combination regimens that include drugs displaying in vitro activity against the K. pneumoniae isolates (eg, aminoglycosides, colistin, fosfomycin, and/or tigecycline) and/or drugs to which K. pneumoniae isolates are in vitro resistant (ie, carbapenems), at least in patients with severe infections [12, [31] [32] [33] [34] . Furthermore, the prevalence of resistance to 1 or more of the few drugs considered active against carbapenem-resistant K. pneumoniae isolates is increasing. Worrisome rates of colistin resistance have recently been reported, especially among KPC-Kp isolates, and data from the European Antimicrobial Resistance Surveillance System for 2016 revealed resistance to this drug in 10%-25% of carbapenem-resistant K. pneumoniae isolates in at least 4 southern European countries, including Italy [15, 35, 36] . Against this unsettling backdrop, CAZ-AVI emerges as a potentially powerful addition to clinicians' antibacterial armamentarium, particularly in hospitals such as those taking part in this study, where KPC-Kp infections are endemic. The cohort we analyzed is the largest sample of patients with CAZ-AVI-treated KPC-Kp infections analyzed to date. As such, Abbreviations: BSI, bloodstream infection; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IQR, interquartile range; KPC-Kp, Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae. a Cohorts were matched for days before salvage therapy (± 1 day) and Pitt bacteremia scores (± 1 point) at the start of salvage therapy.
b BSI whose source was unidentified or located in structures other than the urinary or biliary tract.
c As assessed at the start of salvage therapy. even with the well-known limitations of a retrospective study, it can provide valuable insights into the clinical role of this drug. It is also important to recall, however, that our data reflect CAZ-AVI's performance within the confines of compassionate-use/expanded-access programs, which means that the drug was started only after other antibacterial treatment regimens had failed or could be not continued. In patients with severe gram-negative infections, delayed initiation of active treatment has been associated with poorer outcomes [12, 37] . Therefore, survival in our cohort might reasonably be expected to be worse than those recorded in settings where CAZ-AVI could be started promptly after infection onset. Instead, the 30-day mortality rate we observed (34.1%) is identical to that reported in patients whose CRE infections were treated with CAZ-AVI as the first-line antibiotic regimen [23] . It is also in line with the all-cause in-hospital mortality rate of 39.5% reported in other patients who were managed with CAZ-AVI salvage therapy [22] , even though the delay in starting CAZ-AVI in that study was almost twice as long as that in our cohort (median, 13 vs 7 days from infection onset). In the 37 CAZ-AVI-treated CRE infections they analyzed, Shields et al reported a rate of recurrences in 5 of 37 cases (13.5%), which is quite similar to our experience in the present study, where infection relapses occurred in 12 of the 138 (8.7%) [23] . Furthermore, 3 of 37 (8.1%) cases reported by Shields et al were associated with acquired in vitro resistance to CAZ-AVI (MICs >8 μg/mL) [23] whereas, in our cohort, this event occurred only in 3 of 138 (2.2%) KPC-Kp isolates. It is important to acknowledge that these differences may reflect the use of CAZ-AVI predominantly in different types of infections (bacteremia in our study and pneumonia in that of Shields et al); Shields et al did not observe resistance in bacteremia, whereas 2 cases of resistance in this study occurred in pneumonia; also, in our cohort, 1 of 3 cases of resistance to CAZ-AVI occurred in a patient with pneumonia, although the total number of cases of pneumonia (13/138) was very low compared to cases of BSI (104/138) in our study [23] . In addition, pneumonia has been recently recognized as risk factor for CAZ-AVI resistance among patients with CRE infections [24] .
CAZ-AVI also produced encouraging results in the KPC-Kp BSIs that made up approximately 75% of the cases in our cohort.
Comparison of these cases with a matched cohort of KPC-Kp BSIs treated with other second-line antimicrobial regimens revealed significantly lower 30-day mortality in the CAV-AZI-treated patients. Two previous studies have compared the outcomes of first-line CAZ-AVI treatment with those of other antimicrobial regimens in patients with CRE bacteremia [26, 27] . All 109 cases retrospectively analyzed by Shields et al consisted of carbapenem-resistant K. pneumoniae BSIs. Although only 13 (11.9%) of these infections were treated with regimens that included CAZ-AVI, the rate of clinical success at 30 days in this small subgroup (85%) significantly exceeded those achieved in the other treatment-defined subgroups (P = .006) [26] . This is fully consistent with the striking difference in 30-day survival observed between our BSI cases and controls (Table 2 ) and with the emergence of CAZ-AVI treatment as the sole independent predictor of clinical success in our multivariable logistic regression model. Our findings are also in line with those of van Duin et al, who prospectively analyzed 137 CRE infections (almost half of which involved bacteremia) treated with colistin-containing vs CAZ-AVI-containing regimens [27] . After 30 days of treatment, better outcomes were found to be more likely in the CAZ-AVI-treated group (adjusted probability, 64%). It should be stressed, however, that the latter group was substantially smaller than the one managed with colistin (38 vs 99), and it included only 15 patients with BSIs.
In conclusion, data on this relatively large multicenter cohort indicate that CAZ-AVI is likely to be an important option for treating serious KPC-Kp infections, particularly those involving bacteremia. Although the drug was administered in a compassionate-use setting-that is, only after other antimicrobial regimens had failed-its use was associated with clear survival benefits relative to other commonly used regimens. Further work is needed to devise strategies for the optimal use of this important new drug in the treatment of CRE infections.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. A, Survival in patients whose definitive treatment regimens included ceftazidime-avibactam (CAZ-AVI; black curve) was significantly better than that of patients treated with other antimicrobial drug regimens (gray curve) (P < .001). B, The difference remained significant after adjustment for the presence of septic shock at the start of salvage treatment (P < .001).
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